Prostamax is a four-amino-acid peptide from the Khavinson bioregulator program. The sequence, Lys-Glu-Asp-Pro, is consistent across the papers that state it.
Prostamax Prices
6 vendors · 0 with an issuer-verified COA · lowest 10mg from $40.08 · checked
Where to buy Prostamax: 6 vendors compared
| Vendor | Price | Actions |
|---|---|---|
| $40.0810mg packageChecked today | Buy Prostamax from Regenix Peptides | |
| $51.99 | Buy Prostamax from Cenexa Labs | |
| $54.00 | Buy Prostamax from American Peptides | |
| $55.24 | Buy Prostamax from SomaChems | |
| $59.42 | Buy Prostamax from Evolve Peptides | |
| $71.97 | Buy Prostamax from BioLongevity Labs |
Tracked every day
Prostamax listing prices, tracked daily
The five cheapest in-stock package prices for Prostamax on each collected day, and the vendors that most often held those places.
No collected listings for this compound yet.
Current market data
Prostamax Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Prostamax is $40.08 from Regenix Peptides. The median across vendors is $54.62.
- Lowest 10mg cost
- $40.08Regenix Peptides
- Median 10mg cost
- $54.62One normalized offer per vendor
- Lowest package total
- $40.08Regenix Peptides · package size may differ
- Public COA coverage
- 100%6 of 6 vendors
What the market shows
PeptidePrices found 6 in-stock listings from 6 vendors, checked through Oct 8, 2026. The lowest 10mg cost is 27% below the vendor median of $54.62; 3 vendors (50%) fall below that median. 6 of 6 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Prostamax? Research, safety, and status
Prostamax is a synthetic tetrapeptide: lysine, glutamic acid, aspartic acid, proline. The 2013 rat paper describes it as a new tetrapeptide made by peptide synthesis, not an extract. Like the rest of the family, it is proposed to act by loosening condensed chromatin and reactivating genes that switch off with age.
The developers' 2021 systematic review never names Prostamax. It mentions KEDP once, in a passage on how peptides with mixed acidic and basic residues shift DNA melting temperature. A 2023 paper from the group scored KEDP among the best ligands for the LAT1, LAT2 and PEPT1 transporters in computer docking. That is a modeling result, not measured uptake.
Key research takeaways
Most of its indexed research is not about the prostate. It is chromatin work in blood lymphocytes from elderly donors, done largely by a Tbilisi genetics group that has collaborated with Khavinson.
The one prostate study we found is a 2013 rat model of chronic aseptic prostatitis, published in a small open-access journal. It reports less swelling, inflammation and scarring after 15 days of treatment.
No human trial exists in PubMed or ClinicalTrials.gov. We found no US patent for this sequence, unlike Bronchogen, Cardiogen and Livagen.
Online sources mis-cite the literature. One widely linked wiki page attaches the wrong title, authors and journal to the main PubMed record.
Prostamax at a glance
PeptidePrices safety rating
6/10 · Not FDA-approved
Mechanism
Proposed prostate-tissue bioregulator; lymphocyte studies report chromatin decondensation effects in cells from older donors.
Research areas
Prostate-tissue and male-reproductive bioregulator research. Human clinical benefit is not established.
Regulatory / research status
Research / preclinical only
Half-life
Not established in direct human pharmacokinetic studies.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
Human safety data is sparse. The available evidence is mainly preclinical and small Russian studies from one research group, and it does not establish clinical efficacy.
Russian bioregulator; short peptide; limited but clean data. Human evidence is thin and mostly from one research group. Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- Prostamax is a four-amino-acid peptide from the Khavinson bioregulator program. The sequence, Lys-Glu-Asp-Pro, is consistent across the papers that state it.
- Most of its indexed research is not about the prostate. It is chromatin work in blood lymphocytes from elderly donors, done largely by a Tbilisi genetics group that has collaborated with Khavinson.
- The one prostate study we found is a 2013 rat model of chronic aseptic prostatitis, published in a small open-access journal. It reports less swelling, inflammation and scarring after 15 days of treatment.
- No human trial exists in PubMed or ClinicalTrials.gov. We found no US patent for this sequence, unlike Bronchogen, Cardiogen and Livagen.
Selected references
- Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications · DOI, 2013
- PubChem. Prostamax, CID 9848296 · pubchem.ncbi.nlm.nih.gov
- Effects of short peptides on lymphocyte chromatin in senile subjects · PubMed, 2004
- Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro) [in Russian] · PubMed, 2012
- Peptide regulation of gene expression: a systematic review · PubMed, 2021
- Feasibility of transport of 26 biologically active ultrashort peptides via LAT and PEPT family transporters · PubMed, 2023
Related pages